Bristol Myers Gets FDA OK For Opdivo in First-Line Gastric Cancer Treatment
By Colin Kellaher
The U.S. Food and Drug Administration on Friday said it approved
expanded use of Bristol Myers Squibb Co.'s blockbuster cancer drug
Opdivo for the first-line treatment of gastric cancer.
The agency said the approval covers Opdivo in combination with
certain types of chemotherapy for the initial treatment of patients
with advanced or metastatic gastric cancer, gastroesophageal
junction cancer and esophageal adenocarcinoma, making Opdivo the
first FDA-approved immunotherapy for the first-line treatment of
The FDA said Opdivo is the first treatment in more than a decade
to show a survival benefit for patients with advanced or metastatic
gastric cancer who are being treated for the first time, adding
that there are roughly 28,000 new diagnoses of gastric cancer a
year in the U.S.
Opdivo, which harnesses the body's own immune system to fight
cancer, is currently approved in more than 65 countries across
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
April 16, 2021 13:29 ET (17:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.